Medicare and drug pricing

New England Journal of Medicine

Volumn 348, Issue 16, 2003, Pages 1590-1597

  Iglehart, John K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BOTULINUM TOXIN A; CARBOPLATIN; DEXAMETHASONE SODIUM PHOSPHATE; DOCETAXEL; DOLASETRON MESILATE; DOXORUBICIN; FOLINATE CALCIUM; GEMCITABINE; GOSERELIN; GRANISETRON; HEPARIN; IMIGLUCERASE; IMMUNOGLOBULIN; IPRATROPIUM BROMIDE; IRINOTECAN; LEUPRORELIN; NAVELBINE; ONDANSETRON; PACLITAXEL; PAMIDRONIC ACID; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; SALBUTAMOL SULFATE; TOPOTECAN;

BUDGET; DRUG COST; GOVERNMENT; HEALTH CARE POLICY; HOSPITAL PURCHASING; HUMAN; INDUSTRIALIZATION; MEDICAL PRACTICE; MEDICARE; ONCOLOGY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; QUALITY CONTROL; REIMBURSEMENT; REVIEW;

EID: 0037451910     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMhpr035135     Document Type: Review

References (39)

1. Levit K, Smith C, Cowan C, Lazenby H, Sensenig A, Catlin A. Trends in U.S. health care spending, 2001. Health Aff (Millwood) 2003;22(1):154-64.
2. Gabel J, Levitt L, Holve E, et al. Job-based health benefits in 2002: some important trends. Health Aff(Millwood) 2002;21(5):143-51.
3. Strunk BC, Ginsburg PB, Gabel JR. Tracking health care costs. Bethesda, Md.: Health Affairs, September 26, 2001. (Accessed March 28, 2003, at http://www.healthaffairs.org/WebExclusives/Strunk_web_Excl_92601.htm.)
4. Iglehart JK. Changing health insurance trends. N Engl J Med 2002;347:956-62.
5. Fuhrmans V, Hensley S. Price controls in Europe draw drug makers' criticism. Wall Street Journal. December 13, 2001:B4.
6. Fuhrmans V, Naik G. Applying pressure: drug makers fight to fend off cuts in European prices. Wall Street Journal. June 7, 2002:1.
7. Japsen B. Suits name Abbott, Baxter: fraud alleged in drug pricing. Chicago Tribune. November 22, 2001.
8. Kowalczyk L. Lawsuit targets 28 drug makers. Boston Globe. December 21, 2001.
9. Freudenheim M. Inquiry into drug-sales practices is widened. New York Times. May 13, 2002:C5.
10. Burton TM, Lueck S. Insurer to cover drugs bought outside U.S. Wall Street Journal. October 11, 2002:B1.
11. Prescription Access Litigation. Lawsuits: April 2001 to July 2002. Boston: Community Catalyst, 2002. (Accessed March 10, 2003, at http://www.prescriptionaccesslitigation.org.)
12. Naik G, Fuhrmans V. How Americans may subsidize Euro-health care. Wall Street Journal. December 26, 2002:A8.
13. Pear R. Drug industry is told to stop gifts to doctors. New York Times. October 1, 2002:A1.
14. Idem. Drug makers battle a U.S. plan to curb rewards for doctors. New York Times. December 26, 2002:A1.
15. Cloud DS, McGinley L. How drug makers influence Medicare reimbursements to doctors. Wall Street Journal. September 27, 2000:B1.
16. Report to Congressional committees. Medicare payments for covered outpatient drugs exceed providers' costs. Washington, D.C.: General Accounting Office, September 2001. (GAO-01-1118.)
17. Gencarelli DM. Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism? National health policy forum issue brief. No. 775. Washington, D.C.: George Washington University, June 2002.
18. Appropriateness of Medicare prescription drug allowances. Washington, D.C.: Office of Inspector General, Department of Health and Human Services, May 1996. (OEI-03-95-00420.)
19. Excessive Medicare payments for prescription drugs. Washington, D.C.: Office of Inspector General, Department of Health and Human Services, December 1997. (OEI-03-97-00290.)
20. The impact of high-priced generic drugs on Medicare and Medicaid. Washington, D.C.: Office of Inspector General, Department of Health and Human Services, July 1998. (OEI-03-97-00510.)
21. Medicare reimbursement of albuterol. Washington, D.C.: Office of Inspector General, Department of Health and Human Services, June 2000. (OEI-03-00-00311).
22. Medicare reimbursement ofend stage renal disease drugs. Washington, D.C.: Office of Inspector General, Department of Health and Human Services, 2000. (OEI-03-00-00020.)
23. Medicare reimbursement ofprescription drugs. Washington, D.C.: Office of Inspector General, Department of Health and Human Services, January 2001. (OEI-03-00-00310.)
24. Nicola TJ. Regulatory and legislative history of Medicare drug reimbursement based on average wholesale price. Memorandum written by request of the House Energy and Commerce Committee. Washington, D.C.: Congressional Research Service, 2001.
25. McGinley L, Cloud DS. U.S. to reduce payments for Medicare-covered drugs. Wall Street Journal. June 2, 2000:B6.
26. Medicare, Medicaid and SCHIP Balanced Budget Refinement Act of 1999, Pub. L. No. 106-113, appendix F, 113 Stat. 1501, 1501A-350.
27. Medicare, Medicaid and SCHIP Benefits Improvement and Protection Act of 2000, Pub. L. No. 106-554, appendix F, 114 Stat. 2763, 2763A-508.
28. House Committee on Energy and Commerce Subcommittees on Health and Oversight and Investigation. Medicare drug reimbursements: a broken system for patients and taxpayers: joint hearing before the Subcommittee on Health and the Subcommittee on Oversight Investigations of the Committee on Energy and Commerce, House of Representatives, 107th Congress, first session, September 21, 2001. Washington, D.C.: Government Printing Office, 2001.
29. Scanlon WJ. Medicare part B drugs: program payments should reflect market prices. Testimony before the House Energy and Commerce Subcommittees on Health and Oversight and Investigations, September 21, 2001, Washington, D.C.
30. Grob GF. Testimony before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations on Medicare payments. Washington, D.C.: Office of Inspector General, Department of Health and Human Services, September 21, 2001.
31. Albert H. Letter to Representative W.J. Tauzin. Washington, D.C.: Office of Inspector General, Department of Health and Human Services, June 20, 2001.
32. Iglehart JK. Medicare's declining payments to physicians. N Engl J Med 2002;346:1924-30.
33. Reform of the Medicare payment methods for cancer chemotherapy. Alexandria, Va.: American Society of Clinical Oncology, May 2001.
34. Centers for Medicare & Medicaid Services. Medicare program: revisions to payment policies under the physician fee schedule for calendar year 2003 and inclusion of registered nurses in the personnel provision of the critical access hospital emergency services requirement for frontier areas and remote locations. Fed Regist 2002;67:79973.
35. Report to congressional committees. Medicare physician fee schedule: practice expense payments to oncologists indicate need for overall refinements. Washington, D.C.: General Accounting Office, October 2001. (GAO-02-53.)
36. Tauzin B, Bilirakis M, Greenwood J. Letter to Thomas Scully, administrator. Baltimore: Centers for Medicare & Medicaid Services, November 14, 2001.
37. Analysis of Ways and Means staff proposal on Medicare payment for drugs. Alexandria, Va.: American Society of Clinical Oncology, 2002.
38. DMEPOS competitive bidding demonstration. Baltimore: Centers for Medicare & Medicaid Services, 2003. (Accessed March 28, 2003, at http://www.cms.gov/healthplans/research/dmebid.asp.)
39. Pear R. Bush to propose sweeping changes in Medicare plan. New York Times. January 3, 2003:A1.